Eaton Vance Worldwide Health Sciences remains a solid source of global exposure to healthcare stocks rather than an outstanding one. The strategy retains its People and Process ratings of Average.
Eaton Vance Worldwide Health Sci A ETHSX
- NAV / 1-Day Return 14.84 / +0.95 %
- Total Assets 1.0 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.140%
- Distribution Fee Level Below Average
- Share Class Type Front Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.11%
- Turnover 21%
USD | NAV as of Jul 26, 2024 | 1-Day Return as of Jul 26, 2024, 11:48 PM GMT+0
Morningstar’s Analysis ETHSX
Will ETHSX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 55.2
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 10.36 | 105.4 Mil | Healthcare |
Novo Nordisk A/S Class B | 7.54 | 76.6 Mil | Healthcare |
UnitedHealth Group Inc | 6.99 | 71.1 Mil | Healthcare |
AstraZeneca PLC | 5.39 | 54.7 Mil | Healthcare |
AbbVie Inc | 5.02 | 51.0 Mil | Healthcare |
Thermo Fisher Scientific Inc | 4.94 | 50.2 Mil | Healthcare |
Intuitive Surgical Inc | 4.05 | 41.1 Mil | Healthcare |
Danaher Corp | 3.98 | 40.5 Mil | Healthcare |
Boston Scientific Corp | 3.58 | 36.4 Mil | Healthcare |
Sanofi SA | 3.33 | 33.8 Mil | Healthcare |